Trans bodies and intimacy

Language first

Ask what words a person uses for their body and use those words. Common choices include front hole, girldick, strapless, chest, T-dick, junk, or ordinary anatomical terms. Getting this right is not politeness; mismatched language is one of the most frequently reported causes of dysphoria during sex in survey work on trans sexual health.

Gender identity, sexual orientation and body configuration are three separate axes. Knowing one tells you little about the others, and nothing about what a person likes.

Testosterone: documented physical effects

Within 1–6 months of starting testosterone, most people experience clitoral growth of roughly 1–3 cm (bottom growth), increased libido, and vaginal tissue changes. Atrophic changes — thinning epithelium, reduced elasticity, raised pH — are common and were quantified by Baldassarre et al. (2013), who found reduced maturation index and increased atrophy on vaginal biopsy in trans men on testosterone.

Practical implications:

• Penetration can become painful even where it previously was not. This is a tissue effect, not a psychological one.
• Topical oestrogen locally does not meaningfully reverse masculinisation and is used safely by many trans men for atrophy; discuss with a prescriber.
• Lubricant use should be assumed rather than negotiated.
• Testosterone is not a contraceptive. Pregnancy on testosterone is documented (Light et al., 2014, found 24 percent of a pregnant trans men cohort conceived while amenorrhoeic on testosterone).

Oestrogen and anti-androgens: documented effects

Erections become less frequent, less firm and less reliably spontaneous — often within 1–3 months. Ejaculate volume drops and may cease. Many people report a shift toward more diffuse, full-body, less genitally focused arousal and a longer build. Testicular volume decreases; fertility declines and should be treated as likely to be permanently affected, so gamete storage is discussed before starting where fertility matters.

Libido changes vary in direction. Where low libido is distressing, checking testosterone suppression depth, oestradiol level, prolactin and thyroid function is more useful than assuming it is psychological.

Hormone therapy is not contraception in either direction.

After surgery

• Vaginoplasty: penile inversion and peritoneal techniques both produce a neovagina requiring lifelong dilation, most intensively in the first year. Sensation is usually retained in the neoclitoris, constructed from glans tissue. Reported orgasmic capacity after vaginoplasty is high across series — commonly 70–90 percent — though follow-up periods vary. The neovagina is not self-lubricating in penile-inversion technique; lubricant is required. Depth varies; positions should be chosen accordingly. Bacterial balance differs from a natal vagina and unusual discharge should be checked.
• Phalloplasty and metoidioplasty: sensation returns gradually over 6–24 months as nerves regenerate; erogenous sensation is generally preserved where the clitoral nerve is incorporated. Phalloplasty may involve an erectile implant, with its own device precautions. Urethral complications (fistula, stricture) are common enough to plan around.
• Chest surgery and orchiectomy: nipple sensation after double incision with free nipple grafts is frequently reduced or absent, often partially recovering over 1–2 years. Chest sensation elsewhere can remain or increase.

Ask before touching surgical sites, and ask again over time as healing changes what is comfortable.

Dysphoria during sex

Practical, evidence-informed strategies people report as effective: agreed vocabulary; clothing kept on; lighting and mirror control; positions that avoid dysphoric contact; barriers and toys that change the felt relationship to a body part; a no-questions-asked stop word; and planned aftercare. Dysphoria can arrive mid-encounter with no warning — treat stopping as neutral.

Safer sex specifics

• Trans women on oestrogen may find condoms harder to keep on with softer erections; internal condoms used by the receptive partner solve this.
• Neovaginal tissue can tear; the STI risk profile is not zero and screening should be site-specific (throat, rectum, neovagina or front hole, urethra), which many services still get wrong. Ask for three-site testing explicitly.
• PrEP is effective for trans people; a 2020 analysis of iPrEx data and subsequent work found gender-affirming hormones do not clinically reduce tenofovir/emtricitabine efficacy, and PrEP does not reduce hormone levels.
• Cervical screening is needed if a cervix is present, regardless of gender marker; trans men are significantly under-screened and more likely to have inadequate samples, so a longer appointment, self-swab HPV testing where offered, and topical oestrogen beforehand are reasonable requests.

Sources

• Coleman E et al. "Standards of Care for the Health of Transgender and Gender Diverse People, Version 8." International Journal of Transgender Health, 2022.
• Baldassarre M et al. "Effects of long-term high-dose testosterone administration on vaginal epithelium." International Journal of Impotence Research, 2013.
• Light AD et al. "Transgender men who experienced pregnancy after female-to-male gender transitioning." Obstetrics & Gynecology, 2014.
• Grant JM et al. and James SE et al. US Transgender Survey reports, 2011 and 2015.
• Deutsch MB (ed.). UCSF Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People, 2nd edition.
• Hess J et al. "Sexuality after male-to-female gender affirmation surgery." BioMed Research International, 2018.
• Peitzmeier SM et al. "Pap test use and cervical cancer screening adequacy among female-to-male patients." Journal of General Internal Medicine, 2014.
• Grant RM et al. and Hiransuthikul A et al. on PrEP and gender-affirming hormone interactions, 2016–2020.

Last reviewed: August 2026.